ABC PCN

The registered population is younger than Maidstone and projected to grow 9.7% by 2030

ABC PCN registers 49,850 patients. The list is younger than benchmarks: 15.7% (7,801 patients) are aged 65+, below Maidstone (18.7%), NHS Kent and Medway ICB (19.9%) and England (17.9%), while 21.8% are aged 0–17 (Maidstone 21.5%, ICB 20.7%, England 19.6%). Projected list growth to 2030 is 9.7% using an unverified method, above Maidstone (5.8%), the ICB (6.0%) and England (2.3%). Resident Census data shows 87.2% White and 12.8% from ethnic minority groups, led by 6.2% Asian residents (Maidstone 4.7%, ICB 4.7%, England 9.6%). These figures reflect resident areas, not registered-patient ethnicity.

All registered Core20 deprivation concentrates in The College Practice at 21.2%

The PCN Core20 cohort is 14.3%, above Maidstone (9.9%) but below NHS Kent and Medway ICB (17.1%) and England (21.0%), with an average IMD decile of 5.7 (Maidstone 5.9; England 5.5). Deprivation is concentrated in The College Practice (21.2% share; 7,041 estimated patients), spanning a 21.2 pp range against Aylesford Medical Centre and Blackthorn (both 0.0%). Practice estimates (7,041) and resident LSOA estimates (6,791) rest on different bases.

PLUS groups and inclusion health

The PCN records 608 patients on the severe mental illness register (1.2% vs 1.0% England) and 287 on the learning disability register (0.6% vs 0.6% England). Catchment care homes comprise 28 sites with 1,167 beds, though site and bed capacity figures do not establish occupancy or registered resident numbers.

Severe mental illness: physical health checks

Severe mental illness prevalence is 1.2% (England 1.0%). Physical checks show 83.3% had blood pressure checked (England 83.4%), 85.1% BMI (England 82.1%), and 85.5% alcohol recorded (England 81.8%). Blood pressure checks reach 79.9% at The College Practice.

Clinical focus: hypertension and lipids

Hypertension case-finding and control

Recorded hypertension prevalence is 14.6% (7,109 patients), below Maidstone (16.0%), NHS Kent and Medway ICB (16.2%) and England (15.2%). Over 2023 to 2025, the register fell 2.0%, trailing England (+5.6%) and Maidstone (+4.3%). Practice prevalence ranges from 13.1% at The College Practice to 18.4% at Blackthorn. For diagnosed patients, 90.2% have a recent blood pressure reading (England 90.0%) and 70.7% are treated to target (England 70.3%), rising +5.5 pp over three years (England +2.5 pp).

Lipids and statins

Patients with QRISK ≥ 20% on lipid-lowering therapy reach 61.9%, above Maidstone (60.3%) and NHS Kent and Medway ICB (61.4%) but below England (63.6%). In diabetes aged 40+ without cardiovascular disease, statin treatment is 77.4% (England 73.2%).

For lipid-modifying drugs, PCN cost per item is £1.65, above Maidstone (£1.59) but below England (£1.82) and NHS Kent and Medway ICB (£1.86). Across 68,679 items, the PCN spends £11,675 less than at England's unit cost.

Clinical focus: respiratory, cancer register and children

Respiratory

Asthma prevalence is 5.4% (2,466 patients; Maidstone 6.1%, England 6.6%). Annual reviews gained +7.8 pp over 2023 to 2025 to 63.2% (England 65.7%), leaving about 910 patients without a recorded review. Second-hand smoke status recording in ages 6-19 reached 73.0% (England 78.8%). Paediatric asthma drug prescribing is 782 items per 1,000 aged 5-19 (Maidstone 1,220, England 1,488). COPD prevalence is 1.6% (773 patients; England 1.9%) with 74.4% reviewed (England 76.4%).

Cancer register and children's immunisation

Cancer register prevalence is 3.6% (1,771 patients; Maidstone 4.3%, England 3.8%). In Q1 2025/26 supplementary data, age-5 MMR dose 1 reached 95.6% (NHS Kent and Medway ICB 92.7%, England 91.7%), meeting the 95.0% target. However, dose 2 was 85.2% (ICB 84.4%, England 82.8%), a 10.4 pp difference and 9.8 pp below target. At 24 months, MMR dose 1 reached 88.4% (England 88.3%).

Early cancer diagnosis

In 2022, NHS Kent and Medway ICB diagnosed 55.6% of staged cancers at stage 1 or 2 (4,661 of 8,384), in line with England (55.3%) but below the 75.0% national ambition by 2028 by 19.4 pp, representing an ICB shortfall of 1,627 early-stage cases. Known stage was recorded for 63.6% of registered cancers (England 67.0%). These system-level figures describe regional registry data rather than PCN performance. Locally, cervical screening coverage in women aged 25 to 49 fell 6.0% over 2023 to 2025 (England -1.0%) to 65.6% (The College Practice 63.1%), trailing Maidstone (70.9%), while breast screening reached 70.2% (Maidstone 73.0%).

Cancer waits, diagnostics and community services

Cancer waits and diagnostics, Jul 2026 (provisional)

In July 2026, Maidstone and Tunbridge Wells NHS Trust met the 62-day referral to treatment standard at 87.4%, ahead of Medway NHS Foundation Trust (81.6%), Dartford and Gravesham NHS Trust (63.6%), NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%). The trust achieved 81.8% on the 28-day faster diagnosis standard and 98.3% on the 31-day standard. For diagnostic waits, 6.4% waited 6+ weeks across all tests (England 23.1%), though colonoscopy reached 19.8% and gastroscopy 24.0%. These provider metrics describe acute system performance rather than PCN delivery.

Phone access spans 32.7 pp and vaccination achievement spans 26.8 pp across practices

In 2025/26, QOF overall achievement ranged from 93.5% at The College Practice to 96.7% at Aylesford Medical Centre (England 92.5%). Clinical achievement reached 99.8% to 100.0% (England 97.1%), but vaccination achievement spanned 26.8 pp, from 44.4% at The College Practice to 71.2% at Aylesford Medical Centre (England 55.2%).

Fifteen of 25 measures trail England over three years despite strong clinical reviews

Fifteen of 25 tracked measures trailed England's three-year change from 2023 to 2025. Relative contractions in recorded registers led the lags, including stroke (-11.1% vs +2.3% in England), COPD (-4.9% vs +2.6%), hypertension (-2.0% vs +5.6%), and dementia (-1.2% vs +6.0%). Conversely, clinical reviews improved faster than national benchmarks, led by asthma reviews (+14.1% vs +4.4% in England) and heart failure reviews (+13.3% vs +8.7% in England), reaching 85.6% (England 78.5%). Register contractions could reflect coding variance, unverified locally; register audits would test this.

What the data can't tell us: gaps and local assets

Options for the PCN

Each option in full

Provenance and audit trail

Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

Data sources

Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

Methods, data-quality notes and limitations